Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 9/20 | 0.42 |
| ▸ | CA1 | P00915 | 2/20 | 0.39 |
| ▸ | CA2 | P00918 | 2/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.37 |
| ▸ | ACSS2 | Q9NR19 | 1/20 | 0.36 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.36 |
| ▸ | SYK | P43405 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30425565 | 0.84 | PTGS2 (0.44) | PTGS2CA1CA2CA12CA9 | |
| SCHEMBL24266365 | 0.84 | PTGS2 (0.44) | PTGS2CA1CA2CA12CA9 | |
| SCHEMBL26072706 | 0.81 | PTGS2 (0.37) | PTGS2HDAC6PTGS1GRM2SYK | |
| SCHEMBL31576225 | 0.81 | PTGS2 (0.37) | PTGS2HDAC6PTGS1GRM2SYK | |
| SCHEMBL25362338 | 0.79 | JAK2 (0.44) | PTGS2CA1CA2CA12CA9 | |
| SCHEMBL25365825 | 0.79 | PIM1 (0.42) | PTGS2PTGS1SYK | |
| SCHEMBL26072789 | 0.78 | PTGS2 (0.42) | PTGS2PTGS1SYK | |
| SCHEMBL31578493 | 0.78 | PTGS2 (0.48) | PTGS2CA1CA2CA12CA9 | |
| SCHEMBL25368562 | 0.78 | PTGS2 (0.48) | PTGS2CA1CA2CA12CA9 | |
| SCHEMBL25364475 | 0.78 | PLAT (0.40) | PTGS2SYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250163054-A1 | SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF TLR9 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-05-22 | — | — | US | disclosed |
| EP-4479407-A1 | SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF TLR9 | Bristol-Myers Squibb Company (US) | 2024-12-25 | — | — | EP | disclosed |
| WO-2023159153-A1 | SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF TLR9 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-08-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250163054-A1 | SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF TLR9 | TLR9, TLR3, TLR1 | PTGS2 957/4885CA1 4809/4885CA2 3514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.